University of Mississippi

eGrove
Honors Theses

Honors College (Sally McDonnell Barksdale
Honors College)

2015

Discovery of Resistance-Reversing Agents in Antibiotic Resistant
Strains of Escherichia coli and Klebsiella pneumoniae from
Natural Product Libraries
Andrew B. Watkins
University of Mississippi. Sally McDonnell Barksdale Honors College

Follow this and additional works at: https://egrove.olemiss.edu/hon_thesis
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Watkins, Andrew B., "Discovery of Resistance-Reversing Agents in Antibiotic Resistant Strains of
Escherichia coli and Klebsiella pneumoniae from Natural Product Libraries" (2015). Honors Theses. 1251.
https://egrove.olemiss.edu/hon_thesis/1251

This Undergraduate Thesis is brought to you for free and open access by the Honors College (Sally McDonnell
Barksdale Honors College) at eGrove. It has been accepted for inclusion in Honors Theses by an authorized
administrator of eGrove. For more information, please contact egrove@olemiss.edu.

DISCOVERY OF RESISTANCE-REVERSING AGENTS IN ANTIBIOTIC
RESISTANT STRAINS OF ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE
FROM NATURAL PRODUCT LIBRARIES

by
Andrew Braxton Watkins

A thesis submitted to the faculty of the University of Mississippi in partial fulfillment of
the requirements of the Sally McDonnell Barksdale Honors College.

Oxford
May 2015

Approved by
_____________________________
Advisor: Dr. Alice Clark
_____________________________
Reader: Dr. Melissa Jacob
_____________________________
Reader: Dr. Colin Jackson

© 2015
Andrew Braxton Watkins
ALL RIGHTS RESERVED

	
  

ii	
  	
  

	
  

From my first breath to the completion of my thesis, I have been blessed by the
wonderful love and support of my family. This thesis is dedicated to my parents, Richard
and Angie Watkins, as well as to my grandmother, Shirley Pace. Without their loving
guidance, I would not be here today.

	
  

	
  
iii	
  

	
  

ACKNOWLEDGEMENTS
I would like to express my deepest gratitude to Dr. Melissa Jacob, without whom this
thesis would not have been possible

Thanks also to:
Sally McDonnell Barksdale Honors College
National Center for Natural Products Research
The University of Mississippi School of Pharmacy
Dr. Alice Clark
Mrs. Maria Bennett
Ms. Marsha Wright
Dr. Xing-Cong Li
Dr. Ameeta Agarwal
Dr. Travis King
Dr. Katie Barber
Dr. Colin Jackson
Dr. Debra Young

	
  

	
  
iv	
  

	
  

ABSTRACT
ANDREW B. WATKINS: Discovery of Resistance-Reversing Agents in Antibiotic
Resistant Strains of Escherichia coli and Klebsiella pneumoniae from Natural Product
Libraries
(Under the direction of Dr. Melissa Jacob)
Objective: The objective of this exploratory research is to discover compounds,
particularly from natural products, that inhibit ESBL, KPC, and NDM-1 mechanisms of
antibiotic resistance in the Gram negative bacteria Escherichia coli and Klebsiella
pneumoniae.
Methods: This objective will be accomplished utilizing a high-volume bioassay testing
natural product samples from the National Center for Natural Products Research. This
assay tests samples against 6 different strains of bacteria known to express β-lactamases
in the presence and absence of sub-inhibitory concentrations of the test antibiotic. By
structuring the assay in this way, differentiation may be made between the inherent
antibacterial activity of samples and the synergistic effects between the sample and the
antibiotic. Optical density (OD) readings will be used to determine bacterial growth or
the lack thereof. Samples showing pronounced activity only in the presence of the
antibiotics will be considered active and will be tested in a checkerboard assay to confirm
activity.
Results: Of over 5,000 samples tested, 35 samples showed synergistic activity, giving a
hit rate of 0.7%. Of these 35, the most promising three hits were tested in follow-up
checkerboard assays. These three samples all demonstrated synergistic effects with
fractional inhibitory concentrations (FIC) of <0.5. Of the samples tested in the
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checkerboard assays, one was a plant extract, one was a pure compound, and one was a
fungal soil isolate obtained from the National Cancer Institute.
Conclusions: This study showed the benefits of using a high-volume screen to test
samples against resistant bacterial strains. Continued research in this field could prove to
be beneficial to the discovery of new drugs for clinically relevant therapeutic
applications.
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CHAPTER I
INTRODUCTION
History of Antibiotics
Antibiotics are arguably one of the most important and impactful discoveries in
the field of medicine; however, due to repeated and prolonged antibiotic misuse and
complex genetic mechanisms within bacteria, resistance to these antibiotics has emerged,
spread, and become a serious problem worldwide in many different settings.1 According
to the Center for Disease Control and Prevention’s (CDC) Antibiotic Resistance Threats
in the United States, 2013, over 2 million people per year develop serious infections with
bacteria that are resistant to the antibiotics usually used to treat such infections. At least
23,000 people die directly from these infections, and many more die from other
conditions or complications brought about by these infections. It is estimated that
infections with resistant bacteria cost the United States as much as $20 billion per year in
direct costs, as well as $35 billion per year (2008 economy dollars) in productivity loss
and additional costs.2 It is possible that these numbers have risen even more in the years
since this report. Therefore, there is an urgent need for the discovery and development of
new antibiotics to address the threat of resistant bacteria.1
Although antibiotics and their uses are viewed predominately as a “recent”
occurrence, evidence has suggested that they have been used in some capacity for
thousands of years. Researchers actually found traces of tetracycline, a 20th century
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antibiotic produced by Streptomyces bacteria, in the soil and in bones and enamel of
skeletons from ancient Sudanese Nudia from the years 350-550 AD as well as in
skeletons from Dakhleh Oasis, Egypt, dating back to the late Roman period. These
findings indicate that it is possible that tetracycline may have been consumed in its
natural form from soil. Moreover, it is interesting to note that there was a low rate of
infectious disease documentation in the Sudanese Nubian records, and there were no
signs of bone infection in the remains from Dakhleh Oasis, which points to the possibility
of a protective effect of tetracycline, or other natural remedies, on these ancient peoples.
More evidence of the ancient use of antibiotics is the discovery of antibiotic substances
found in soils and herbs from folk stories and from Traditional Chinese Medicine
therapies.3
Ancient peoples may have used plants and other natural substances as a type of
antibiotic, but the actual “antibiotic era” did not begin until the early to mid 1900’s.
Crucial discoveries such as Paul Ehrlich’s method of testing numerous compounds
against a common microbe or target in a screen or bioassay laid the foundation for
antibiotic development, including the discovery of Salvarsan used to treat syphilis.3
Subsequent screening programs by chemists of the Bayer company, leading to the
discovery of Pronotsil, and the quintessential serendipitous discovery of penicillin in
1928 by Royal Army Medical Corps veteran Alexander Fleming ushered in the age of
antibiotics.4 Fleming was one of the first people to warn about the dangers of antibiotic
resistance in penicillin if the drug was used in quantities too small or for time periods too
short.3
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Emergence of Antibiotic Resistance
Although the aforementioned antibiotics may be different and carry different
stories of their discoveries, there lies an underlying factor that connects them to each
other as well as to all other used antibiotics: resistance. According to the World Health
Organization (WHO), antimicrobial resistance refers to the resistance to antimicrobial
drugs by the common microorganisms that would usually be treated with the drug.
Antibiotic resistance is simply a more specific subtype of antimicrobial resistance in
which bacteria become resistant to antibiotics.5 Although antibiotic resistance has been
hastened in recent years due to widespread misuse, it has been found that it is a naturally
occurring phenomenon present even before the commercial use of penicillin.1,5 In a study
in 2006, a group of scientists sampled bacteria from different soils in different
environments, and found that many of the collected strains were resistant to multiple
classes of antibiotics, both synthetic and natural, including new antibiotic drugs. This
study showed the wide variety of antibiotic resistance mechanisms present naturally in
soil microbes. These resistance mechanisms most likely evolved as competitive defense
mechanisms against naturally produced antibiotics, but now they could further develop
into clinically significant resistance problems.6
A factor that makes antibiotic resistance even more of a problem is the ability of
bacteria to exchange genes that code for mechanisms that cause resistance. Resistance is
usually present in certain bacterial strains in the form of an endogenous protein able to
inhibit the mechanism of action of an antibiotic compound. This protein is produced via
translation of an mRNA transcript transcribed from a resistance gene. Resistance genes
such as these are usually brought into the cell from the outside environment or from
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another bacterium in the form of a plasmid.7 A plasmid is a circular piece of DNA that
exists separately from normal chromosomal DNA, is replicated separately, and can be
passed horizontally to other bacteria through the process of conjugation. In this process of
conjugation, a projection called a sex pilus extends from one bacterium to another and
connects the two cells. A DNA pore is then formed, and a plasmid is replicated and
transferred to the new cell, giving each cell a copy of the plasmid. When such a plasmid
contains a gene that encodes resistance, it is called a “resistance plasmid,” and the
transfer of such a plasmid can be an efficient way to spread antibiotic resistance to
different strains of bacteria. Another mechanism for the acquisition of resistance is
through random genetic mutations in the host bacterium. These random insertions,
deletions, or inversions of DNA nitrogenous bases can result in serious mutations in
genes, and if these mutations happen to impart resistance and an advantage in survival,
they will be passed to all subsequent generations. This method of resistance acquisition
follows Darwin’s theory of natural selection, and is a major driving force behind
antibiotic resistance.8

Factors Affecting Resistance in Today’s Society
The occurrence of natural selection in resistant microbes can be problematic even
when it is left to act alone, but it can become even more of a problem with the addition of
man-made selective pressures such as antibiotic misuse and abuse. In cases like these, the
incorrect use of antibiotic drugs can increase the spread of resistance. When an antibiotic
attacks a group of bacteria, the susceptible bacteria are killed, leaving only those bacteria
that are resistant to the drug. These resistant bacteria, with no competitors present, are
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able to thrive and reproduce to form a new colony consisting solely of resistant bacteria.
This problem is even more prevalent when antibiotics are administered in too low of a
dose or when patients do not take a full course of antibiotic treatment, as correctly
predicted by Fleming.9 According to a large meta analysis conducted by Kardas et al., the
overall antibiotic therapy compliance rate of patients was 62.2%. The same study found
that 28.6% of the included patients used “leftover” antibiotics from previous infections.10
Low compliance rates such as these provide ample opportunities for resistant bacterial
communities to develop and thrive by the mechanism previously discussed. The problem
of resistance can also be worsened by the incorrect prescription of antibiotic drugs by
physicians. The CDC estimates that 50-150 million antibiotic prescriptions per year are
unneeded, and a seminar conducted by Levy found that over 80% of physicians had
prescribed antibiotics on demand against better judgment.9 This flooding of the
population with antibiotics also helps develop and spread resistance.
Two other factors that contribute to resistance are agricultural applications of
antibiotics and overuse of antibacterial cleaning supplies. Antibiotics are used extensively
in agriculture to promote the growth and development of livestock that are to be used for
food. The use of these antibiotics, even in low quantities, puts selective pressure on
populations of bacteria, leading to the development of resistance. Through the excretions
of livestock, these bacteria can enter the water source where they can be spread directly
or indirectly to humans through ingestion or irrigation of other edible plants.11 The spread
of resistant strains combined with the capabilities of bacteria to transfer resistance
plasmids creates a situation that can lead to clinically relevant types of resistance. As the
desire to keep surfaces and bodies clean and free from bacteria has risen, so too has the
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use of antibiotic-containing cleaning supplies.12 Many of these supplies include triclosan,
an antibacterial compound with broad spectrum activity that many believe may contribute
to antibacterial resistance. Triclosan was found to be one of the most common
pharmaceutical chemicals present in water samples from 139 rivers in the United States
in 1999-2000, which testifies to the extent of its use.13 Research has suggested that it has
some non-specific activity, but also works on a specific target, giving it the possibility of
promoting resistance to other antibiotics. The potential for this cross-resistance in
clinically relevant strains of bacteria is rather small, but it is still a possibility and should
be taken seriously. Because of triclosan’s widespread use and its possibility of conferring
cross-resistance, research is being conducted to determine the benefits and detriments of
its use, and caution should be taken when using large quantities of substances containing
triclosan.12
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Chapter II
Literature Review
Clinically Relevant Mechanisms of Resistance
There are many different bacterial mechanisms that confer antibiotic resistance;
because of this, the CDC organized the known mechanisms into a hierarchy of clinical
significance in a report from 2013. In this report, they listed resistant strains of bacteria as
“urgent,” “serious,” or “concerning” threats.2 Mechanisms relevant both clinically and to
this project include carbapenem-resistant Enterobacteriaceae [CRE] (urgent threat) and
extended-spectrum β-lactamase producing Enterobacteriaceae [ESBL’s] (serious threat).
A subtype of the CRE’s, called NDM-1, is emerging as a dangerous and clinically
significant mechanism. All of these mechanisms are present in Enterobacteriaceae, a
family of gram-negative bacteria including Escherichia coli, Klebsiella pneumonia, and
many other strains of bacteria.14 Strains from this family are able to cause pneumonia,
blood and wound infections, and meningitis.15 All of these mechanisms also involve the
production of an enzyme known as β-lactamase. β-lactamase is an enzyme that is able to
disable β-lactam antibiotics (e.g. penicillins) by hydrolyzing the β-lactam ring within the
compound and is responsible for a large number of resistance mechanisms. These βlactamase enzymes are classified in different ways, the simplest of which is the Ambler
system, established in 1980. This system categorizes enzymes into four classes (A, B, C,
D) based on their amino acid sequences. Class A β-lactamases include broad spectra,
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extended-spectra, and carbapenemase enzymes from both plasmids and chromosomal
DNA; Class B enzymes are metallo-β-lactamases such as NDM-1; Class C enzymes are
cephalosporinases coded for in chromosomal DNA; and Class D enzymes are
oxacillinases.16 The classes most relevant to the CDC report are Class A and Class B βlactamases.
Among the “urgent threat” strains of bacteria exist the carbapenem-resistant
Enterobacteriaceae (CRE).2 Carbapenems are very important and effective broadspectrum antibiotics that historically have had no problems with resistance; however, the
recent development of carbapenem-hydrolyzing β-lactamases has increased the
occurrence of resistance.14,16 The most common carbapenemase now is the Klebsiella
pneumoniae carbapenemase (KPC), a Class A enzyme that is very capable of inactivating
β-lactam antibiotics. KPC-producing bacteria were first seen in North Carolina in 2001
and in the following years were seen throughout the Northeastern United States. As of
2010, KPC-producing microbes have been reported or received from 36 states,
Washington DC, and Puerto Rico. Beginning in 2006, reports from foreign countries also
showed the presence of KPC-producing bacteria. Studies and sample analyses have
shown that in the United States, approximately 70% of KPC-producing bacteria belong to
the same dominant strain.14
As mentioned previously, Class B enzymes are called metallo-β-lactamases
(MBL’s). These enzymes are different from Class A enzymes because of their use of zinc
to hydrolyze the β-lactam ring.14 A unique MBL, the New Delhi Metallo-β-Lactamase
(NDM-1), has arisen from this class and is proving to be a problematic mechanism
because of its ability to inactivate all β-lactam antibiotics except for aztreonam.14,17 The
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first known case of NDM-1-producing bacteria was found in 2007 in a Swedish patient
that had been treated in a hospital in New Delhi, India; soon thereafter, NDM-1 producers
were seen in the United Kingdom, India, and Pakistan.17 Many of the UK patients
infected with NDM-1-producing bacteria were previously treated in India or Pakistan,
demonstrating the speed with which resistant microbes can be transferred from one
country to another.14,17 One of the factors that distinguishes NDM-1 from other resistance
mechanisms is its tendency to spread to numerous unrelated bacterial strains. It has been
seen in E. coli and K. pneumoniae, as well as other species of the same family. Another
clinical problem presented by NDM-1 is its tendency to occur in bacterial strains that
possess resistance to many other antibiotics, making these strains resistant to many, and
possibly all, clinically used antibiotic therapies. Many strains carrying the NDM-1 gene
are vulnerable only to colistin and tigecycline. There have been only small numbers of
cases in multiple countries around the world, but the potential to spread is very high.17
This potential for international travel mixed with the extent of resistance provided by
NDM-1 makes bacterial strains containing this mechanism of resistance extremely
dangerous and an urgent threat.
A third distinct clinical threat is the spread and emergence of extended-spectrum
β-lactamase (ESBL)-producing Enterobacteriaceae strains. These strains produce βlactamases that are able to inactivate a variety of newer β-lactam antibiotics, including
third-generation cephalosporins (such as cefotaxime) and monobactams (such as
aztreonam).18 Many of these strains are also able to obtain resistance genes that confer
resistance to other classes of antibiotics while still keeping the resistance to older
antibiotics. Because of their ability to become more resistant and their frequent presence

	
  

9	
  

	
  

in human infections, ESBL-producing K. pneumoniae and E. coli were listed by the
Infectious Diseases Society of America as microbes that need new treatment options as
soon as possible.19 Most ESBL’s are separated into three groups (TEM, SHV, and CTXM) based on the gene in which there is a mutation.18,20 Bacteria displaying CTX-Mmediated resistance are not limited to hospital infections, and the epidemiology of such
bacteria is very different than that of bacteria with TEM or SHV resistance.18 TEM and
SHV derived ESBL’s both arise from one or more amino acid substitution(s) on their
respective genes. TEM ESBL’s are very common in E. coli and are one of the most
common mechanisms of resistance against β-lactam antibiotics in gram-negative bacilli
worldwide. The SHV family of β-lactamases is widespread in K. pneumonia, and actually
originated in the chromosomes of species of the Klebsiella genus before being
incorporated into a plasmid and spread to other Enterobacteriaceae.20 The three genes
cannot be differentiated by phenotypic measures and therefore must be genotyped for
identification.18,20 These three different types of ESBL-producing genes vary in their
degree of resistance and susceptibility to certain antibiotics, but all convey resistance and
are proving to be clinically-relevant threats.20

Reversing Resistance and Current Research Methodologies
Although antibiotic resistance is a growing problem, there is a sense of hope in
the form of resistance-reversing compounds. Currently, these compounds are relatively
rare, but research is being conducted to discover new agents that could be marketed for
use in infections caused by resistant strains of bacteria.16 Some of the most prominent
types of resistance-reversing agents in ESBL-producing bacteria are the β-lactamase
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inhibitors. As their names imply, these compounds work by preventing the activity of βlactamases, thereby restoring the activity of β-lactam antibiotics.21 Currently, there are
three commercially available β-lactamase inhibitors: clavulanic acid (clavulanate),
sulbactam, and tazobactam.16 As seen in Figure 2-1, these compounds all contain a βlactam ring similar to that present in β-lactam antibiotics, but have little inherent
antibacterial activity.16,21
Figure 2-1: Commercially Available β-Lactamase Inhibitors

Source: Watkins R, Papp-Wallace K, Drawz S, Bonomo R. Novel β-lactamase inhibitors: A therapeutic
hope against the scourge of multidrug resistance. Front Microbiol. 2013 24 December 2013;4

When in the presence of β-lactamases, these compounds irreversibly bind to the
enzymes (using their inherent β-lactam structure), thereby permanently disabling the βlactamases and “protecting” the antibiotics. This mechanism is responsible for the
restored activity of antibiotics against resistant bacteria when in the presence of these
compounds. There are different combinations of antibiotics and β-lactamase inhibitors,
the most popular of which is clavulanate/amoxicillin, available orally under the name
Augmentin as well as under various other trade names. These compounds are effective
against Class A ESBL’s except for the carbapenemases, but are ineffective against Class
C and most Class B and Class D β-lactamases.21 Because of its resistance-reversing
activity, a β-lactamase inhibitor such as clavulanate can be used in combination with a β-
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lactam antibiotic such as cefotaxime to phenotypically identify ESBL-producing bacteria
or to inhibit bacterial colony growth.22 This application could be useful as a positive
control in screens detecting resistance-reversing compounds.
While the previous compounds work well with many Class A ESBL’s, they lack
effectiveness against carbapenemase-resistant Enterobacteriaceae (CRE); however,
boronic acids are a group of compounds known to reverse carbapenem resistance.16
Boronic acid (BA) compounds have been known to reversibly bind to and inactivate βlactamases; however, recent studies have shown that this mechanism can lead to the
inactivation of carbapenemases such as KPC.23 A specific boronic compound, 3aminophenylboronic acid (APB), has been found to be very successful in phenotypically
determining KPC-producing bacteria through the use of disk-based assays by adding an
antibiotic to a small disc and placing it on a petri dish with bacteria and comparing the
zone of inhibition to that of a disk with the same antibiotic plus APB. According to one
study, this works very well when the carbapenem used is meropenem; zones of inhibition
were increased by more than 5mm in all KPC-producing strains when APB was
combined with meropenem. The increase in zone of inhibition in the combination of
meropenem and APB versus meropenem alone shows that the APB is able to work
synergistically to restore or increase the activity of meropenem.24 The CDC has also seen
similar results in combinations of APB with carbapenems in their research efforts. In one
study, the MIC of meropenem in a KPC-producing strain of K. pneumoniae was reduced
16.67-fold upon addition of APB (meropenem alone = 2 µg/mL; meropenem+APB =
0.12 µg/mL).25 The ability of boronic acid compounds, especially APB, to synergistically
work to restore activity to carbapenems, especially meropenem, provides a desirable
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positive control for screens testing for resistance-reversing effects. However, as yet, BA
is only effective in the laboratory and development of clinically used BA compounds is in
its early stages, with only one product approaching clinical trials.16
One of the more difficult mechanisms of resistance to overcome is NDM-1
mediated resistance. The NDM-1 lactamase is a metallo-β-lactamase, meaning that it
requires zinc to hydrolyze β-lactam antibiotics. This makes MBL’s such as NDM-1 very
problematic for chemists, which is shown by the few numbers of inhibitors present today.
Few in vivo clinical inhibitors have been described over the years, but there are some
promising in vitro possibilities, one of which is ethylenediamine-N,N,N’,N’-tetraacetic
acid (EDTA). EDTA has well-known chelating properties, meaning that it can bind and
remove metal ions, such as the zinc required for NDM-1 cleavage of β-lactams. Although
this chelating effect makes EDTA useful in inhibiting NDM-1 and other MBL’s, it also
causes major concerns about toxicity when used clinically. Because of the large number
of human metalloproteins, non-specific chelation by an agent such as EDTA could cause
serious biological harm.26 One in vitro use is the phenotypic detection of MBL-producing
bacteria via disk assays and observation of zones of inhibition. Studies have shown that
EDTA can work synergistically with imipenem, a type of carbapenem drug, to inhibit
growth of MBL-producing bacteria.27 The synergistic effect of EDTA with carbapenem
drugs could prove to be very useful as a positive control in future resistance-reversing
assays.
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Chapter III
Methods
Preparation of Samples
Plant samples were delivered to the National Center for Natural Products
Research (NCNPR) from various sources, including the Missouri Botanical Garden in St.
Louis, MO, freeze-dried, ground, and stored in the sample repository. Ground material
was extracted using the Accelerated Solvent Extraction System (ASE, Dionex) with 95%
ethanol three times under 1500 psi at 40°C for 10 minutes. The ethanol extracts were
evaporated using a Rocket evaporation system (SP Scientific) with final drying in the
HT-12 evaporator (SP Scientific). Extracts were stored in dimethyl sulfoxide (DMSO) at
20mg/mL at -80°C in 96-well plates for testing. A portion of this extract (~150-200mg)
was sent to St. Jude Children’s Research Hospital in Memphis, Tennessee, while the rest
was kept in the repository for future use.
At St. Jude, the delivered plant extracts were fractionated as described by Tu et al.
Briefly, samples had polyphenols removed using a 700 mg polyamide-filled cartridge
(Sigma-Aldrich, St. Louis, MO) and a 48-place positive pressure SPE manifold (SPEware
Corporation, Baldwin Park, CA). Approximately 100 mg of extract were dissolved and
added to the cartridge. The column was washed with five column values of methanol, and
the effluent was dried using a stream of nitrogen from a Zymark TurboVap LV
Concentration Workstation. After this prefractionation step, fractions were dissolved in 2
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mL of DMSO. Samples were separated into 24 fractions using High-performance liquid
chromatography (HPLC) and collected in preweighed 16 X 100 mm glass tubes. HPLC
was performed on a Gemini 5 µm C18 110A column, and a Shimadzu LC-8A binary
preparative pump with a Shimadzu SCL-10A VP Controller was connected to the Gilson
215 auto sampler and Gilson 215 fraction connector. A Shimadzu SPD-M20A diodearray detector and a Shimadzu ELSD-LT II evaporative light scattering detector were
used to perform detections. The fractions were sent to the NCNPR in deep 96-well plates
at 2 mg/mL in DMSO. These samples are referred to as COMBI’s and were later tested
as such.28
In addition to NCNPR plant extracts and COMBIs, other samples tested in this
project include microbial extracts from the National Cancer Institute (NCI), a collection
of pure compounds isolated at NCNPR, and the FDA Approved Drug collection
(SelleckChem).

Selection and Preparation of Bacterial Strains
Before a bioassay was designed, a preliminary literature review was conducted to
determine the best possible strains to include in the study. After reviewing the available
literature, it was determined that strains of Klebsiella pneumoniae and Escherichia coli
were high priority research targets because of their clinical relevance in infections. It was
also determined that the most important mechanisms of resistance were attributed to the
β-lactamases (ESBL, KPC, and NDM-1). Bacterial strains were acquired from the
American Type Culture Collection (ATCC) and include Klebsiella pneumoniae 700603,
Klebsiella pneumoniae BAA-1705, Klebsiella pneumoniae BAA-2146, Escherichia coli
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BAA-201, Escherichia coli BAA-2340, and Escherichia coli BAA-2452. These strains,
their mechanisms of resistance, and the positive controls used in the screens can be found
in Table 3-1. The strains were suspended in broth, spread on a Eugon agar plate, and
allowed to incubate for 24 hours. The plates were then stored at 4°C until needed for
assays. Fresh agar plates were prepared each week from frozen bacterial stocks. These
bacteria were tested using Clinical and Laboratory Standards Institute (CLSI) methods.
Briefly, bacterial strains were diluted and their optical densities (OD) were recorded
using a Biotek Powerhouse XS Plate Reader. These diluted solutions were then added to
agar plates in such a way that individual colonies could be counted. These recordings
were done in triplicate to create a calibration curve to which all OD measurements could
be compared to yield a colony-forming unit (CFU)/mL value. This procedure was done to
ensure that in theory, every well in every assay contained a similar number of CFU’s (5.0
X 105/mL), which provides consistency in testing.

Table 3-1: Tested Strains, Mechanisms of Resistance, and Positive Controls
Mechanism of
Bacterial Strain
Test Antibiotic
Positive Control
Resistance
Klebsiella
SHV-18 ESBL
Cefotaxime
Clavulanate
pneumoniae 700603
Klebsiella
3-Aminophenyl
pneumoniae BAAKPC-1
Meropenem
boronic acid
1705
Klebsiella
pneumoniae BAANDM-1
Meropenem
EDTA
2146
Escherichia coli
TEM-3 ESBL
Cefotaxime
Clavulanate
BAA-201
Escherichia coli
3-aminophenyl
KPC
Meropenem
BAA-2340
boronic acid
Escherichia coli
NDM-1
Meropenem
EDTA
BAA-2452
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Developing and Conducting the Bioassay
To determine the ideal sample and antibiotic concentration combinations for the
primary screen, preliminary checkerboard assays were performed. These tests were run in
all six strains of bacteria with twofold serial dilutions of the appropriate test antibiotic
and positive control compound. Different concentrations of antibiotic and positive control
were used in different strains based on information obtained during a literature review.
Graphs of the results of these optimizing checkerboards can be found in the Appendices.
The assay was designed to test samples against bacteria in the presence and
absence of a sub-inhibitory concentration of the test antibiotic. By doing this, inherent
antibacterial activity of the test sample could be separated from synergistic resistancereversing effects of the sample in combination with the antibiotic.
Test samples from stored plates were diluted in saline at the same concentration
and 4 µL of the samples and controls were transferred in duplicate to a 384-well plate by
the Tecan Evo liquid automated handler to afford final test concentrations of 20-40
µg/mL for fractions and pure compounds and 80-200 µg/mL for extracts. These 384-well
plates were stored in a 4°C cold room overnight in preparation for the assay. The next
morning, inoculum was prepared in cation-adjusted Mueller-Hinton to afford 5 X 105
CFU/mL and supplemented with either the target concentration of antibiotic or an
equivalent volume of DMSO. These antibiotic concentrations were chosen based on
optimized results from checkerboard studies (shown in appendices) and can be found in
Table 3-2.

	
  

17	
  

	
  

Table 3-2: Antibiotic Concentrations in Bacterial Inocula
Bacterial Strain
Klebsiella pneumoniae
700603
Klebsiella pneumoniae
BAA-1705
Klebsiella pneumoniae
BAA-2146
Escherichia coli
BAA-201
Escherichia coli
BAA-2340
Escherichia coli
BAA-2452

Test Antibiotic

Antibiotic
Concentration (µg/mL)

Cefotaxime

1.0

Meropenem

2.5

Meropenem

5.0

Cefotaxime

5.0

Meropenem

1.0

Meropenem

1.5

Once the inocula (with antibiotic and without antibiotic) were prepared, 50 µL
were added to their designated 384-well plates using a Thermo Scientific Multidrop
Combi. The plates were read at 530 nm prior to and after incubation at 35°C for 24 hours.
Using Microsoft Excel, the percent inhibitions of the samples (compared to blank and
negative controls) were calculated. Samples showing synergizing activity were
considered to have little to no inherent activity alone, but pronounced activity in the
presence of the test antibiotic. These hits were further analyzed in checkerboard assays,
where samples were diluted vertically (down columns), while antibiotic was diluted
horizontally (across rows). Fractional inhibitory concentrations (FIC), which show the
extent of compound synergy, were calculated as described by Li and Rinaldi. FIC’s were
calculated from the IC50s (using XLFit, model 201, Alameda, CA) of the two compounds
alone and in combination using the following formula: FIC = (IC50 of compound A in
combination/IC50 of compound A alone) + (IC50 of compound B in combination/ IC50 of
compound B alone).29 A drug was considered synergistic if its FIC was ≤0.5.
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Chapter IV
Results
Over the course of this research, over 5,000 samples were tested in this bioassay.
A breakdown of the sample types tested can be found in Table 4-1. From these samples,
35 showed activity in the primary assay, giving a hit rate of 0.7%. Table 4-2 shows the
most promising hits from the screens, as well as the strain in which they were active and
the extent of their activity.
Table 4-1: Types of Samples Tested in Primary Assays

	
  

Sample Type

Number of Samples
Tested in Primary Assay

St. Jude COMBI’s

2451

NCNPR Plant Extracts

1048

NCNPR Pure Compounds

264

FDA Collection

88

NCI Microbial Extracts

1232
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Table 4-2: Select Primary Hits with Promising Results
Sample ID

Strain

NPID 68322
(fungal soil isolate)

Escherichia coli
BAA-2452

NPID 143149
Bleomycin sulfate

Escherichia coli
BAA-2452

NPID 127055
Combretum collinum

Escherichia coli
BAA-2452

NPID 57605
Oenothera drummondii

Klebsiella pneumoniae
BAA-2146

NPID 57599
Tamarix chinensis

Klebsiella pneumoniae
BAA-2146

NPID 81943
Sanguisorba officinalis

Klebsiella pneumoniae
BAA-2146

Extent of Activity
100% growth reduction in
combination with
meropenem
73% growth reduction in
combination with
meropenem
48% growth reduction in
combination with
meropenem
47% growth reduction in
combination with
meropenem
40% growth reduction in
combination with
meropenem
35% growth reduction in
combination with
meropenem

	
  
	
  
Three samples displayed potent synergizing activity in checkerboard assays. As
seen in Figure 4-1, all samples tested showed varying degrees of synergistic growth
inhibition, verifying their activities in the primary assay. In this figure, each cell
represents the differences in OD values of “after” readings and “before” readings.
Smaller values (red) represent small increases in OD values and little bacterial growth,
while larger values (green) represent greater differences in OD values and increased
bacterial growth. Well H12 on each plate contained a DMSO control to represent
uninhibited bacterial growth. All compounds tested in checkerboard assays had FIC’s
<0.5, confirming synergism. Since bleomycin sulfate was the only pure compound tested
in the checkerboard assay, it is the only sample with a known structure, seen in Figure 42.	
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Figure 4-1: Checkerboard Assay of Select Hits

	
  

	
  
	
  
Figure 4-2: Bleomycin Sulfate Molecular Structure

Source: http://www.chemicalbook.com/ProductChemicalPropertiesCB8391148_EN.htm
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Chapter V
Discussion
Data Discussion
The primary purpose of this exploratory research was to discover new compounds
capable of reversing bacterial mechanisms of resistance (β-lactamases in particular) and
therefore restoring the activity of clinically used antibiotics. This was accomplished
through the implementation of a new primary screen and subsequent checkerboard assays
of promising hits. While the hit rate for the primary assay was only 0.7%, it seems to be
effective in finding potent hits. This low hit rate is understandable because of the rarity of
resistance-reversing compounds, and may be favorable moving forward with a highvolume screening approach, especially because the NCNPR has over 50,000 samples that
can be tested. The lower percentage of hits will allow reasonable and sustainable
chemical purification and fractionation that could potentially result in therapeutically
effective compounds to be tested in vivo.
One of the most interesting hits was that of a fungal soil isolate obtained from the
National Cancer Institute (NCI). The isolate was unidentified, and contact has been made
to obtain a culture for future assays and identification. Based on these results, the NCI
has elevated this sample for identification studies. Once the culture is received, it will be
grown, extracted, and tested to confirm activity. If activity is confirmed, isolation studies
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will be performed on this sample. Its potent activity and natural source make this sample
a high priority for future research.
Another interesting hit was that of bleomycin sulfate. Bleomycin is a glycopeptide
antibiotic produced by Streptomyces verticillus that is used as an anticancer agent to
cause DNA strand breaks in cancerous cells. Bleomycin resistance genes are usually
found in bleomycin-producing strains, but through genetic exchange they have been
transferred to other bacterial strains, including Enterobacteriaceae. Interestingly, analysis
of NDM-1-containing strains of E. coli has shown a bleomycin resistance gene
downstream of the NDM-1 gene, and it is likely that these genes are coexpressed under a
common promoter.30 The implications of this gene and the bleomycin hits in this bioassay
are unknown, and further research should be conducted to determine the possible
mechanism of action.
The final sample that was tested in a checkerboard assay was a plant extract from
the fruits of Combretum collinum, commonly known as the bushwillow plant. This plant
sample was collected in Kenya, Africa. Studies have shown some antibacterial activity in
this genus, but no studies were found linking this genus or species to NDM-1.31 This lack
of information demands further research on this plant species and its role in antibiotic
resistance reversal.

Limitations
There are over 50,000 samples in the NCNPR repository, but only ~5,000 could
be tested due to time constraints. A majority of the time for this project was dedicated to
multiple troubleshooting experiments towards the development of a robust assay to detect
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resistance-reversing samples. Once conditions (bacterial strain selections, antibiotic test
concentrations, positive control selections) were determined, little time was available for
testing NCNPR samples. Therefore, little comprehensive follow-up studies,
fractionations, and identifications could be performed on the confirmed hits. Because of
the number of hits that were extracts, it would have been very beneficial to fractionate
and retest to find a single compound or a small group of compounds that confer the
resistance-reversing effects of the sample. This will be done in the next stages of the
project. Also, once the NCI fungal isolate was identified as a hit, the NCI was notified to
provide a culture, for which they have to prepare for shipping, and the sample has not yet
been received for confirmation studies. This isolate could be very promising, and its
purification and identification could have greatly added to this study. The lack of time
also limited the number of St. Jude COMBI’s that could be tested. While a large number
of COMBIs were tested, there still remain 35,000. These COMBI’s are very interesting
samples that could result in promising hits. Moreover, the COMBIs have already been
chemically analyzed via UV, ELSD and mass spectrometry, and therefore this data can
serve to facilitate compound identity. Future studies will focus heavily on testing these
COMBI’s for activity.
Another limitation could be the utilization and interpretation of the bioassay used.
This bioassay was designed and the cutoff values and concentrations were recently
developed by the research group. While the initial sub-inhibitory concentrations of the
test antibiotics have been initially determined, it may be necessary to alter these
concentrations if the hit rate is too low (not enough antibiotic is present to achieve
synergy). The antibiotic test concentrations were chosen based on the positive control’s
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ability to reverse resistance. Since in many cases there are complex mixtures of
compounds in the form of crude extracts, and synergizing compounds may be diluted by
inherently active antibacterial compounds, changes to the test antibiotic concentration
may be necessary. As well, the differences in the inhibition of the sample in the presence
and absence of antibiotic (ideally a delta of 100) will be continually evaluated as more
primary data becomes available. Smaller deltas, especially when the sample is unique or
little is known about the extract, may be considered as a hit, and subsequent confirmation
assays will be used to justify if this smaller difference was valid.
A final limitation to this study could be the in vitro approach the bioassay used.
Although very helpful in preliminary drug discovery studies, in vitro techniques provide
no insight into how compounds will work in the body or how safe they may be when
used in humans. Caution must be taken when analyzing these results, as they do not
reflect accurate in vivo results.

Implications
As previously discussed, antibiotic resistance is a growing problem worldwide
that is only getting worse. With the decrease in new antibiotic development, it is crucial
that researchers discover new methods of reversing resistance to ensure positive patient
outcomes and increased patient survival. By implementing high volume screens such as
the one developed for this study, scientists can test large numbers of samples, both
synthetic and natural, with different antibiotics and different strains of bacteria containing
different mechanisms of resistance. While ESBL, KPC, and NDM-1 mechanisms of
resistance are very dangerous and clinically relevant in today’s society, there are also
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numerous other mechanisms that could be tested with similar screens. There are also
many pathogenic strains of bacteria other than K. pneumoniae and E. coli that could be
tested in a similar fashion. This screening format is convenient because of its ease and
efficiency, as well as the large number of samples it can test per assay. Tests such as
these run in multiple laboratories worldwide will result in a large breadth of samples to
be tested, identified, and purified.
Questions still remaining after the completion of this study are the identities of
active compounds within samples. Compounds need to be isolated using a bioassayguided fractionation method, a common bottleneck in natural product research, and these
isolated compounds should be tested to determine their mechanisms of action. These
issues will be addressed in future studies, as this is an ongoing research project.
Future research in the field may hope to expand this study to include more
realistic health models and to optimize the screen. Future tests should also include in vivo
testing to discover toxicity issues and possible therapeutic uses for active compounds. By
focusing efforts on testing active compounds in vivo, researchers can move closer to
discovering clinically significant therapeutic compounds. Future research should also
focus on different strains of bacteria and different mechanisms of resistance to ensure
diverse and comprehensive discoveries. The arms race against bacterial resistance
mechanisms is ever changing, and only through innovative thinking and research
strategies can researchers and clinicians hope to overcome the clinical challenges
presented by antibiotic resistance.
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Appendix A: Checkerboard Assay of Klebsiella pneumoniae 700603 (ESBL) using
Cefotaxime (Cefo) and Clavulanate (Clav) [FIC = 0.06]

Figure AA-1: Relative Optical Densities at 530 nm

Axes values represent concentration in µg/mL

Figure AA-2: Graph of Checkerboard Results
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Appendix B: Checkerboard Assay of Escherichia coli BAA-201 (ESBL) using
Cefotaxime (Cefo) and Clavulanate (Clav) [FIC = 0.05]

Figure AB-1: Relative Optical Densities at 530 nm

Axes values represent concentration in µg/mL

Figure AB-2: Graph of Checkerboard Results
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Appendix C: Checkerboard Assay of Klebsiella pneumoniae BAA-1705 (KPC) using
Meropenem (Mero) and 3-Aminophenyl boronic acid (BA) [FIC = 0.35]

Figure AC-1: Relative Optical densities at 530 nm

Axes values represent concentration in µg/mL

Figure AC-2: Graph of Checkerboard Results
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Appendix D: Checkerboard Assay of Escherichia coli BAA-2340 (KPC) using
Meropenem (Mero) and 3-Aminophenyl boronic acid (BA) [FIC = 0.2]

Figure AD-1: Optical Densities at 530 nm

Axes values represent concentration in µg/mL

Figure AD-2: Graph of Checkerboard Results	
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Appendix	
  E: Checkerboard Assay of Klebsiella pneumoniae BAA-2146 (NDM) using
Meropenem (Mero) and EDTA [FIC = 0.07]

Figure AE-1: Optical Densities at 530 nm

Axes values represent concentration in µg/mL

Figure AE-2: Graph of Checkerboard Results	
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Appendix	
  F:	
  Checkerboard Assay of Escherichia coli BAA-2452 (NDM) using
Meropenem (Mero) and EDTA [FIC = 0.02]

Figure AF-1: Relative Optical Densities at 530 nm	
  

	
  

Axes values represent concentration in µg/mL

Figure AF-2: Graph of Checkerboard Results	
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